At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
mifepristone vaginal tabletsdrug
Likely dose
mifepristone vaginal tablets 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Vaginal Mifepristone on Reduction of Uterine Fibroids Size and the Symptoms Associated With the Fibroids - Pilot Study (Phase IIa)
In Brief
A Phase 2 clinical trial evaluating mifepristone vaginal tablets for Uterine Fibroid and Vaginal Bleeding.. Completed, enrolled 30 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of daily dosage of vaginally mifepristone on reduction of uterine fibroids size and the symptoms associated with uterine fibroids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUterine Fibroid, Vaginal Bleeding.
CountriesIsrael
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionMay 2012
Study CompletionJul 2012
TodayJul 2026
First PostedApr 15, 2009
Enrollment StartApr 1, 2009
Primary CompletionMay 1, 2012
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 17.2 years ago
Interventions
mifepristone vaginal tabletsdrug
Daily use of 10 mg administrated per vagina for 3 months